The global cancer cell market has gained significant importance due to the increasing research and development activities in cancer research and drug discovery. Cancer cells are used in pre-clinical research for developing new cancer drugs and for understanding disease pathophysiology which helps drive the market. The cancer cells market consists of various established as well as new cell lines which are used by academic and research institutions and biopharmaceutical companies for understanding cancer mechanisms and developing novel therapies. The global Cancer Cell Market is estimated to be valued at US$ 10799.45 Mn in 2024 and is expected to exhibit a CAGR of 11. % over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the cancer cell market is the rising adoption of 3D cancer cell cultures. 3D cancer cell cultures better mimic the in vivo tumor microenvironment and cell-cell interactions as compared to conventional 2D monolayer cultures. They provide a physiologically relevant model for cancer drug testing and disease modeling. Many companies are actively developing innovative 3D cancer cell culture products and systems to facilitate tumor models for accelerated drug development. For instance, InSphero AG offers 3D tumor microtissue and organoid models for oncology research developed using its GravityPLUS 3D bioprinting platform.
The increased adoption of personalized cancer medicine is also a notable trend in the market. With advanced molecular characterization techniques, personalized therapy involves tailoring treatments based on an individual patient’s genetic profile and tumor biomarkers. This requires development of patient-derived xenograft or organoid models from tumor biopsy samples. Patient-derived cancer cells preserve the heterogeneity and genomic characteristics of the original tumor and enable development of tailored screening platforms for precision oncology. Major players are focusing on expanding capabilities for establishing patient-derived cancer cell biobanks.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is low due to high capital requirements for R&D and manufacturing. Bargaining power of buyers: The bargaining power of buyers is moderate as there are many alternatives available from different players. Bargaining power of suppliers: The bargaining power of suppliers is low due to the availability of substitutes from different suppliers. Threat of new substitutes: The threat of new substitutes is high due to ongoing technological innovations. Competitive rivalry: Competitive rivalry is high owing to the presence of global players in the market.
Key Takeaways
The Global Cancer Cell Market Growth is expected to witness high.
Regional analysis shows North America dominates the market currently owing to high awareness levels and increasing prevalence of cancer. Asia Pacific is expected to grow at the fastest pace during the forecast period due to rising healthcare expenditure and demand.
Key players operating in the cancer cell market are Honeywell International Inc., Siemens AG, General Electric Company, and Schneider Electric SE. Honeywell International Inc. is one of the leading players offering various cancer cell testing instruments like flow cytometers and real-time quantitative PCR systems.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it